[go: up one dir, main page]

MX2024009974A - Esteroides neuroactivos para el tratamiento de trastornos relacionados con el snc. - Google Patents

Esteroides neuroactivos para el tratamiento de trastornos relacionados con el snc.

Info

Publication number
MX2024009974A
MX2024009974A MX2024009974A MX2024009974A MX2024009974A MX 2024009974 A MX2024009974 A MX 2024009974A MX 2024009974 A MX2024009974 A MX 2024009974A MX 2024009974 A MX2024009974 A MX 2024009974A MX 2024009974 A MX2024009974 A MX 2024009974A
Authority
MX
Mexico
Prior art keywords
cns
treatment
related disorders
neuroactive steroids
additional antidepressant
Prior art date
Application number
MX2024009974A
Other languages
English (en)
Inventor
Stephen Jay Kanes
James Doherty
Handan Gunduz-Bruce
Robert Alfonso Lasser
Jeffrey Martin Jonas
Amy E Bullock
Timothy Y Mariano
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of MX2024009974A publication Critical patent/MX2024009974A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente descripción se refiere a métodos para tratar el trastorno depresivo mayor (TDM) o la depresión postparto (DPP) en un sujeto que lo necesite con una combinación del Compuesto (1) y un antidepresivo adicional, seguido de la administración continua del antidepresivo adicional.
MX2024009974A 2022-02-16 2023-02-15 Esteroides neuroactivos para el tratamiento de trastornos relacionados con el snc. MX2024009974A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263310581P 2022-02-16 2022-02-16
US202263337828P 2022-05-03 2022-05-03
US202363482200P 2023-01-30 2023-01-30
PCT/US2023/013098 WO2023158668A1 (en) 2022-02-16 2023-02-15 Neuroactive steroids for treatment of cns-related disorders

Publications (1)

Publication Number Publication Date
MX2024009974A true MX2024009974A (es) 2024-09-30

Family

ID=85569830

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024009974A MX2024009974A (es) 2022-02-16 2023-02-15 Esteroides neuroactivos para el tratamiento de trastornos relacionados con el snc.

Country Status (11)

Country Link
US (1) US20250295674A1 (es)
EP (1) EP4479032A1 (es)
JP (1) JP2025508406A (es)
KR (1) KR20240148425A (es)
CN (1) CN119072304A (es)
AU (1) AU2023220976A1 (es)
CA (1) CA3252357A1 (es)
IL (1) IL315023A (es)
MX (1) MX2024009974A (es)
TW (1) TW202341995A (es)
WO (1) WO2023158668A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2887944B1 (en) 2012-08-21 2021-10-06 Sage Therapeutics, Inc. Allopregnanolone for treating refractory status epilepticus
KR102614507B1 (ko) 2013-04-17 2023-12-19 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
KR20230079470A (ko) 2016-08-23 2023-06-07 세이지 테라퓨틱스, 인크. 결정질 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드
KR20200096596A (ko) 2017-12-08 2020-08-12 세이지 테라퓨틱스, 인크. Cns 장애의 치료를 위한 중수소화 21 -[4-시아노-피라졸-1 -일]-19-노르-프레간-3. 알파-올-20-온 유도체
IL307991A (en) * 2021-04-29 2023-12-01 Sage Therapeutics Inc 19-NOR C3, 3- di-converted C21-N-pyrazolyl steroid for use in the treatment of major depressive disorder and postpartum depression
CN117442618B (zh) * 2023-10-23 2025-11-14 国科大杭州高等研究院 化合物ly2940094在制备治疗中枢神经系统脱髓鞘疾病药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102614507B1 (ko) 2013-04-17 2023-12-19 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
KR20230079470A (ko) 2016-08-23 2023-06-07 세이지 테라퓨틱스, 인크. 결정질 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드
KR20200096596A (ko) 2017-12-08 2020-08-12 세이지 테라퓨틱스, 인크. Cns 장애의 치료를 위한 중수소화 21 -[4-시아노-피라졸-1 -일]-19-노르-프레간-3. 알파-올-20-온 유도체
CN117959309A (zh) * 2018-06-12 2024-05-03 萨奇治疗股份有限公司 19-去甲基c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
CN111454318A (zh) * 2019-01-20 2020-07-28 浙江易众化工有限公司 抗抑郁药物sage-217的晶型及其制备方法
BR112023000990A2 (pt) 2020-07-20 2023-03-28 Sage Therapeutics Inc Formulações de esteroide c21-n-pirazolil 19-nor c3,3- dissubstituído e métodos de uso das mesmas

Also Published As

Publication number Publication date
IL315023A (en) 2024-10-01
CN119072304A (zh) 2024-12-03
KR20240148425A (ko) 2024-10-11
JP2025508406A (ja) 2025-03-26
US20250295674A1 (en) 2025-09-25
EP4479032A1 (en) 2024-12-25
WO2023158668A1 (en) 2023-08-24
AU2023220976A1 (en) 2024-09-05
TW202341995A (zh) 2023-11-01
CA3252357A1 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
MX2024009974A (es) Esteroides neuroactivos para el tratamiento de trastornos relacionados con el snc.
MX2023007027A (es) Derivado de cannabinoide como compuesto farmaceuticamente activo y metodo de preparacion del mismo.
MX2022015613A (es) Composiciones de benzofurano beneficiosas para trastornos mentales o mejoramiento mental.
MX2022000733A (es) Derivados cannabinoides como compuestos farmaceuticamente activos y metodos de preparacion de los mismos.
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
MX2022013698A (es) Dispositivos de administracion transdermica de farmacos que contienen psilocibina, dietilamida de acido lisergico o microprotuberancias recubiertas con 3,4-metilendioximetanfetamina.
BR112023022264A2 (pt) Esteroide c21-n-pirazolil 19-nor c3,3-dissubstituído e métodos de uso do mesmo
ECSP22086300A (es) Composiciones que comprenden nanopartículas, método de elaboración y usos de las mismas
MX2020012008A (es) Métodos para potenciar la biodisponibilidad y la exposición de un abridor de canales de potasio dependientes de voltaje.
BR112023020669A2 (pt) Terapias de combinação para o tratamento de câncer
BR112022007721A2 (pt) Método para o tratamento da demência
CL2019002313A1 (es) Combinación de cotinina y antioxidante para la resistencia al tratamiento de la depresión y corrección del déficit funcional de los astrocitos inducido por la depresión y otras afecciones neuropatológicas.
MX2021013901A (es) Composiciones y métodos para el tratamiento del cáncer.
CO2023016136A2 (es) Composiciones y métodos para inhibir la expresión del componente 1 de reducción de amidoxima mitocondrial (marc1)
CL2022001102A1 (es) Métodos para el tratamiento de trastornos depresivos.
MX2021002017A (es) Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion.
MX2023009600A (es) Análogos de la oxa-ibogaína para el tratamiento de trastornos por consumo de sustancias.
MX2020012925A (es) Producto inmunogeno que comprende il-4 y/o il-13 para el tratamiento de enfermedades asociadas con la expresion o actividad aberrante de il-4 y/o il 13.
CO2023003533A2 (es) Métodos para el tratamiento de trastornos de mineralización ósea referencia cruzada a solicitudes relacionadas
BR112021010856A2 (pt) Vibegron para o tratamento de sintomas de bexiga hiperativa
MX2021011263A (es) Uso de moduladores del receptor gabaa para el tratamiento del dolor.
CL2023000121A1 (es) Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrófilas
CO2021016931A2 (es) Compuestos para el tratamiento de trastornos neuromusculares
MX2023005342A (es) Métodos para tratar padecimientos relacionados con el receptor s1p1.
BRPI0617382A2 (pt) Métodos para tratar um distúrbio do sistema nervoso central em um paciente, para tratar um paciente sofrendo de condições e uma disfunção sexual, e para reduzir um retardo na eficácia terapêutica em seguida ao início do tratamento